Increasing clarithromycin resistance is dramatically reducing the efficacy of standard triple therapy for Helicobacter pylori eradication. Quadruple therapy is associated with high cure rates, yet its complex administration protocol hampers its acceptability for general use. A recent study has assessed the efficacy and safety of a novel, single-capsule bismuth-containing quadruple therapy.
